TABLE 6

FROM:

Production of cysteinyl-dopamine during intravenous dopamine therapy

Julia L Magnay, Jeff Tong, Rosa Drangova and Andrew D Baines

Table 6. Effect of -glutamyl transpeptidase (GT) in human plasma on conversion of 5-S-glutathionyl dopamine (GSH-DA) to 5-S-cysteinyl dopamine (CYS-DA)

	High GT plasma		High GT plasma + acivicin
Minutes	GSH-DA	CYS-DA	GSH-DA	CYS-DA
0	860	<0.15	860	<0.15
5	356	43	818	6
30	117	108	807	16

	Low GT plasma		Low GT plasma + acivicin
0	860	<0.15	860	<0.15
5	656	<0.15	554	<0.15
30	390	<0.15	392	<0.15

 Concentration is in nmol/L. Glutathionyl-dopamine (GSH-DA) was added to pooled plasma with high (270 U/L) or low (10 U/L) -glutamyl transpeptidase activity. Acivicin (1.5 mg/mL) was added to a paired sample to inhibit -glutamyl transpeptidase activity.